CardioCell's stem cells advance in US, Kazakhstan studies
This article was originally published in Scrip
Executive Summary
CardioCell has initiated a Phase IIa clinical trial in the treatment of acute myocardial infarction (AMI) with its ischemia-tolerant mesenchymal stem cells (itMSCs) and the private San Diego-based company expects to get a lot of valuable data from an ongoing Phase III trial conducted by Kazakhstan's Ministry of Health.